北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (5): 812-816. doi: 10.3969/j.issn.1671-167X.2016.05.011

• 论著 • 上一篇    下一篇

T1a~T1b期前列腺癌的诊断与治疗

刘茁,罗程,胡帅,范宇,刘振华,杨新宇,沈棋,刘漓波,韩文科,周利群,虞巍, 何群,张骞,金杰△   

  1. (北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤研究中心,北京100034)
  • 出版日期:2016-10-18 发布日期:2016-10-18
  • 通讯作者: 金杰 E-mail:jinjie@vip.163.com

Diagnosis and treatment of T1a-T1b prostate cancer

LIU Zhuo, LUO Cheng, HU Shuai, FAN Yu, LIU Zhen-hua, YANG Xin-yu, SHEN Qi, LIU Li-bo, HAN Wen-ke, ZHOU Li-qun, YU Wei, HE Qun, ZHANG Qian, JIN Jie△   

  1. (Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological and Male Reproductive System Cancer Center, Beijing 100034, China)
  • Online:2016-10-18 Published:2016-10-18
  • Contact: JIN Jie E-mail:jinjie@vip.163.com

摘要:

目的:探讨经尿道前列腺电切术后偶发前列腺癌(即T1a~T1b期前列腺癌)的临床病理特点,提高对该病的诊疗认识。方法:回顾性分析2004年5月至2013年9月北京大学第一医院泌尿外科977例因良性前列腺增生(benign prostatic hypertrophy,BPH)而行经尿道前列腺电切手术(transurethral resection of prostate,TURP)患者的临床病理资料,选择其中总前列腺特异抗原(total prostate specific antigen, tPSA)≤10 μg/L,且既往无前列腺或膀胱手术史者共771例,对TURP组织病理标本进行全部取材,由专业病理科医师进行分析,描绘HE染色切片显微镜下的肿瘤轮廓,采用Image J 1.47h软件采集图像,测量肿瘤面积,将每例患者所有切片中的肿瘤面积相加,估算的肿瘤体积等于肿瘤测量面积总和乘以模块厚度。收集患者的临床及病理资料,随访其治疗方式、前列腺特异性抗原(prostate specific antigen, PSA)进展情况、干预治疗的原因及方式、肿瘤特异性病死率等。结果:本组患者发现偶发癌86例,检出率为11.2%,此86例患者肿瘤体积0.4~180.2 mm3,其中T1a期77例(89.5%),平均肿瘤体积为(12.3±12.6) mm3,T1b期9例(10.5%),平均肿瘤体积为(105.1±41.8) mm3。所有患者肿瘤体积均<500 mm3,属于小体积前列腺癌。肿瘤Gleason评分,<7分者79例,≥7分者7例。86例患者初步治疗方案均为等待观察,其中2例失访,中位随访时间88.9个月(27.9~150.1个月)。共5例患者发生PSA进展,其中T1a期4例,T1b期1例,此5例患者均选择干预治疗。T1b期有1例患者虽然未发生PSA进展,但因患者意愿强烈也选择了干预治疗。T1a期患者中,1例选择前列腺根治性切除术,术后未见生化复发;3例选择内分泌治疗,未见治疗后PSA进展。T1b期1例患者选择放疗,未见放疗后生化复发,1例选择内分泌治疗,未见治疗后PSA进展。获得随访的84例患者中非前列腺癌特异性死亡者6例,未见前列腺癌特异性死亡者。结论:本研究偶发癌检出率为11.2%,86例偶发癌均属于小体积前列腺癌,等待观察治疗对T1a~T1b期前列腺癌是一种相对安全的治疗策略。

关键词: 前列腺肿瘤, 前列腺, 经尿道前列腺电切术

Abstract:

Objective:To explore the clinical pathological characteristics and improve the recognition in the diagnosis and treatment of incidental (stage T1a-T1b) prostate cancer. Methods:  Seven hundred and seventy-one patients who underwent TURP from May 2004 to September 2013 were analyzed retrospectively. In our institution, TURP specimens should be totally submitted in an extensive sampling method. The tumor area was outlined by estimation of an experienced genitourinary pathologist and calculated by the image analysis system software (Image J 1.47 h). The tumor area was then multiplied by the thickness of tissue. The total sum of all tumor volume was the estimated tumor volume. The clinical and pathological factors, follow-up results were obtained and we aimed to collect information about the period of watchful waiting (WW), PSA progression status, intervention status during the follow-up, the reason for intervention on WW and the type of intervention.Results:  The average age of 771 patients was (71.3±5.9) years old, and the average BMI was (23.9±3.1) kg/m2, preoperative average tPSA was (4.4±2.8) μg/L. Eighty-six (11.2%) cases of incidental prostate cancer were detected. The patients in T1a group (77 cases, 89.5%) had tumor volumes of (12.3±12.6) mm3, and the patients in T1b group had tumor volumes of (105.1±41.8) mm3.The range of tumor volume was 0.4-180.2 mm3. The volume of all the 86 cases was less than 500 mm3 as the threshold of insignificant cancer. All the patients were managed by WW. The mean followup time was 88.9 (27.9-150.1) months.The Gleason score was <7 in 79 patients, and ≥7 in 7 patients. There was no significant difference in age, preoperative tPSA, preoperative PSAD, postoperative tPSA, prostate volume and TURP resection between T1a group and T1b group (P>0.05). Among 84 patients without follow-up losts, PSA progression occurred in 5 patients. One T1a patient underwent radical prostatectomy (RP) as an intervention, and 3 patients underwent hormone therapy. One patient in T1b group underwent radiotherapy for PSA progression and one was treated because of patient preference without evidence of disease progression. There were no patients who died due to prostate cancer. Conclusion: Eighty-six (11.2%) cases of incidental prostate cancer were detected. The tumor volume of all the cases was insignificant cancer.The clinical outcomes of IPCa were satisfactory with the initial treatment of WW in the Chinese population.

Key words: Prostate neoplasms, Prostate, Transurethral resection of prostate

中图分类号: 

  •  
[1] 李志存, 吴天俣, 梁磊, 范宇, 孟一森, 张骞. 穿刺活检单针阳性前列腺癌术后病理升级的危险因素分析及列线图模型构建[J]. 北京大学学报(医学版), 2024, 56(5): 896-901.
[2] 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报(医学版), 2024, 56(4): 557-561.
[3] 邢念增,王明帅,杨飞亚,尹路,韩苏军. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报(医学版), 2024, 56(4): 565-566.
[4] 田宇轩,阮明健,刘毅,李德润,吴静云,沈棋,范宇,金杰. 双参数MRI改良PI-RADS评分4分和5分病灶的最大径对临床有意义前列腺癌的预测效果[J]. 北京大学学报(医学版), 2024, 56(4): 567-574.
[5] 姚凯烽,阮明健,李德润,田宇轩,陈宇珂,范宇,刘毅. 靶向穿刺联合区域系统穿刺对PI-RADS 4~5分患者的前列腺癌诊断效能[J]. 北京大学学报(医学版), 2024, 56(4): 575-581.
[6] 欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报(医学版), 2024, 56(4): 582-588.
[7] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报(医学版), 2024, 56(4): 589-593.
[8] 于书慧,韩佳凝,钟丽君,陈聪语,肖云翔,黄燕波,杨洋,车新艳. 术前盆底肌电生理参数对前列腺癌根治性切除术后早期尿失禁的预测价值[J]. 北京大学学报(医学版), 2024, 56(4): 594-599.
[9] 薛蔚,董樑,钱宏阳,费笑晨. 前列腺癌新辅助治疗与辅助治疗的现状及进展[J]. 北京大学学报(医学版), 2023, 55(5): 775-780.
[10] 刘毅,袁昌巍,吴静云,沈棋,肖江喜,赵峥,王霄英,李学松,何志嵩,周利群. 靶向穿刺+6针系统穿刺对PI-RADS 5分患者的前列腺癌诊断效能[J]. 北京大学学报(医学版), 2023, 55(5): 812-817.
[11] 毛海,张帆,张展奕,颜野,郝一昌,黄毅,马潞林,褚红玲,张树栋. 基于MRI前列腺腺体相关参数构建腹腔镜前列腺癌术后尿失禁的预测模型[J]. 北京大学学报(医学版), 2023, 55(5): 818-824.
[12] 袁昌巍,李德润,李志华,刘毅,山刚志,李学松,周利群. 多参数磁共振成像中动态对比增强状态在诊断PI-RADS 4分前列腺癌中的应用[J]. 北京大学学报(医学版), 2023, 55(5): 838-842.
[13] 张展奕,张帆,颜野,曹财广,李长剑,邓绍晖,孙悦皓,黄天亮,管允鹤,李楠,陆敏,胡振华,张树栋. 近红外荧光靶向探针用于前列腺神经血管束术中成像[J]. 北京大学学报(医学版), 2023, 55(5): 843-850.
[14] 许素环,王蓓蓓,庞秋颖,钟丽君,丁炎明,黄燕波,车新艳. 等体温膀胱冲洗对经尿道前列腺电切术患者干预效果的meta分析[J]. 北京大学学报(医学版), 2023, 55(4): 676-683.
[15] 刘圣杰,侯惠民,吕政通,丁鑫,王璐,张磊,刘明. 双极雄激素序贯免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌4例[J]. 北京大学学报(医学版), 2022, 54(4): 766-769.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!